Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program - Summary - MDSpire

Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program

  • By

  • Patrick J. Kiel

  • Mark W. McGiffin

  • Todd C. Skaar

  • Michael A. Preston

  • March 10, 2026

  • 0 min

Share

Objective:

Add specific metrics for cost-effectiveness comparison.

Key Findings:
  • Incorporate specific data points or percentages.
Interpretation:

Expand on implications for clinical practice.

Limitations:
  • Clarify how limitations affect study conclusions.
Conclusion:

Suggest specific policy adjustments needed.

Original Source(s)

Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program

  • by Patrick J. Kiel, Mark W. McGiffin, Todd C. Skaar, Michael A. Preston

  • March 10, 2026

Related Content

Trends in colorectal cancer mortality in China from 2004 to 2021: an epidemiological analysis based on national disease surveillance data

Deep learning-enabled multiphoton microscopy predicts colorectal cancer recurrence from routine FFPE specimens

H&E-based MSI/MMR testing with AI in colorectal cancer: a multi-centred blinded evaluation